Roche CEO warns on vaccine optimism and Gilead’s Remdesivir fails first trial
Head of Equity Strategy
Summary: A vaccine takes much longer than the current expectation of 12-18 months according to Roche's CEO. This is bad news for the recovery camp as a vaccine is absolutely critical for society to bounce back to meaningful growth levels post the expected historical drop in economic activity in 2020. In today's US equity session sentiment took a hit when Financial Times reported that Remdesivir, the Gilead Sciences drug that was highlighted last week as a potential candidate for treatment of COVID-19, failed its first trial.
The CEO Severin Schwan of Roche said yesterday in a Bloomberg TV interview in relation to its Q1 revenue figures that a 12-18 months target for a COVID-19 vaccine is very ambitious and history shows it often takes longer time. It’s often the large scale manufacturing that’s the problem and especially for a global market. He also teared apart the current antibody tests for immunity as faulty because they had been rushed to market with too little testing while touting its own test coming to the market in early May as being better tested and more reliable.
Schwan also sounded negative on testing capabilities and that widespread mass testing of new cases of COVID-19 was almost impossible due lack of infrastructure. His expectations on a good COVID-19 vaccine was in our view much more pessimistic than what the market is currently pricing in equities and we are quite surprised that the market hasn’t taken more notice of this. The V-shape recovery camp will have a hard time if a vaccine is not coming fast.
Roche’s Q1 revenue figures yesterday showed the company’s diversified portfolio of drugs and businesses had been resilient so far in 2020 and the company also confirmed its 2020 outlook which is rare given how many companies are abandoning their guidance. With the current free cash flow generation and enterprise value of CHF 304bn the company is offering a 5% free cash flow yield which is impressive for a business with almost zero net debt. The shares closed at an all-time high in today’s session.
As if the pessimistic view from Roche’s CEO was not enough Financial Times reported that Gilead Sciences’ Remdesivir has failed in its first trial as a treatment against COVID-19. The news impacted the entire US equity market as the news last week that the drug had success in a hospital in Chicago lifted the market and Gilead’s shares. However, in our Saxo Market Call podcast on April 17 we did highlight the many arguments for why it was most likely a planted story to boost the shares ahead of option expiry. Gilead has commented that it finds the study inconclusive at this point and will continue to look at the drug. We will most likely have to get used to these very positive stories on health care stocks related to some drug or potential vaccine to treat COVID-19 as the market is huge for the company that get a drug or vaccine first. Sometimes the hype on a bad study is enough to convince governments to purchase a drug or vaccine. Tamiflu for treatment of H1N1 flu was such a case where the governments likely wasted large amount of money on something that turned out be ineffective.
Latest Market Insights
Quarterly Outlook Q3 2022: The Runaway Train
- Central banks' attempts to kill inflation is a paradigm shift, which could end in a deep recession.
Tangible assets and profitable growth are the winnersWith US equities officially in a bear market, the big question is where and when is the bottom in the current drawdown?
Understanding the lack of investment appetite among oil majorsThe everything rally seen in recent quarters has become more uneven, as its strength is driven by commodities in short supply.
The pressure is on as the wind leaves the sailsWith cryptocurrencies in sharp decline, are we entering a crypto winter or is the bear market a healthy clean-up of the crypto space?
Why the Fed can never catch up and what turns the US dollar lower?Many other central banks are set to eventually outpace the Fed in hiking rates, taking their real interest rates to levels higher than the Fed will achieve.
Bank of Japan: Swimming against the tideThe Japanese economy has gone from the age of deflation to rapidly rising prices in no time, leaving the Bank of Japan in a pickle.
Green transformation detour and bear market hibernationWith the impending risk of global econonomic derailment, we share the five things investors need to consider in this new half year.
Crisis redux for the eurozone?Whether there's going to be a recession in Europe or not, the path towards a stable economy will be agonizing.
Technical Outlook: Gold, Oil and a remarkable multi-decade perspective on EquitiesThe Nasdaq bubble pattern, USDJPY resistance, crude oil uptrend losing steam and the technical outlook for USD.
China: the train of new development paradigm left the station two years agoChina is transiting to a new development paradigm, as they are hit by deteriorating terms of trade, a slower global economy and an uncertain future while continuing attempts to contain the pandemic.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)